Andrew Wolf, MD
Ophthalmology · Stamford, CTNPI 1376551051
Payments from drug & device makers
Across 102 payments — averaging $20.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Oyster Point Pharma, Inc.$209
- Sun Pharmaceutical Industries Inc.$203
- Tarsus Pharmaceuticals, Inc.$200
- Bausch & Lomb Americas Inc.$182
- Bausch & Lomb, A Division Of Bausch Health US, LLC$174
- Kala Pharmaceuticals, Inc.$173
- plus $906 from 15 others
What the payments were for
- Food & beverage$2,048100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Oyster Point Pharma, Inc. | 10 | $209 |
| Sun Pharmaceutical Industries Inc. | 11 | $203 |
| Tarsus Pharmaceuticals, Inc. | 8 | $200 |
| Bausch & Lomb Americas Inc. | 10 | $182 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 9 | $174 |
| Kala Pharmaceuticals, Inc. | 8 | $173 |
| AbbVie(2 entities) | 8 | $172 |
| Alcon | 5 | $109 |
| Novartis | 5 | $94 |
| Aerie Pharmaceuticals, Inc. | 4 | $75 |
| Dompe US, Inc. | 3 | $70 |
| Rayner Intraocular Lenses Limited | 4 | $65 |
| Thea Pharma Inc. | 3 | $60 |
| Shire North American Group Inc | 3 | $57 |
| Biotissue Holdings Inc. | 3 | $52 |
| Sight Sciences, Inc. | 2 | $30 |
| Johnson & Johnson Vision Care, Inc. | 2 | $28 |
| ANI Pharmaceuticals, Inc. | 1 | $27 |
| Carl Zeiss Meditec, Inc. | 1 | $26 |
| Harrow Eye, LLC | 1 | $21 |
| Astellas Pharma US Inc | 1 | $21 |
How this compares
$2,048 in reported general payments places this provider in the 70th percentile of 279 ophthalmology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 29 | $1,393 |
| Prednisolone Acetate | 24 | $908 |
| ErythromycinErythromycin Base | 43 | $324 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Stamford
- Gregory GallousisStamford$10K
- Lauren SchneiderStamford$4K
- Robert FucignaStamford$3K
- Matthew PaulDanbury$944K
- Amir CohenNew Haven$441K
- John HuangHartford$390K
- James MurphyHamden$176K
- Anthony DanielsNew Haven$66K
- James TalbotNew Canaan$47K
- Paul KangNew Haven$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.